title: The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain.
abstract: The MATRICS Consensus Cognitive Battery (MCCB), developed by the National Institute of Mental Health (NIMH) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative, has been recommended as the standard battery for clinical trials of cognition-enhancing interventions for schizophrenia. Normative data for the MCCB has been previously obtained in the U.S. Extrapolation of these normative data to different countries may be problematic due to the translation of the different tests, as well as potential cultural influences. We present the process of obtaining normative data for the MCCB in Spain with administration of the battery to a general community standardization sample. In addition, we examine the influence of age, gender, and educational level on test performance. The MCCB was administered to a total sample of 210 healthy volunteers, at three Spanish sites. For each site, recruitment of the sample was stratified according to age, gender, and educational level. Our findings indicate significant age, gender, and education effects on the normative data for the MCCB in Spain, which are comparable to those effects described for the original standardized English version in the U.S. The fact that the normative data are comparable, and that the variables age, gender, and education have a similar influence on performance, supports the robustness of the MCCB for use in different countries.
authors.affiliation: Department of Psychiatry, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain. roberto.rodriguez.jimenez@gmail.com
authors.forename: R
authors.initials: R
authors.lastname: Rodriguez-Jimenez
authors.forename: A
authors.initials: A
authors.lastname: Bagney
authors.forename: C
authors.initials: C
authors.lastname: Garcia-Navarro
authors.forename: A I
authors.initials: AI
authors.lastname: Aparicio
authors.forename: R
authors.initials: R
authors.lastname: Lopez-Anton
authors.forename: M
authors.initials: M
authors.lastname: Moreno-Ortega
authors.forename: M A
authors.initials: MA
authors.lastname: Jimenez-Arriero
authors.forename: J L
authors.initials: JL
authors.lastname: Santos
authors.forename: A
authors.initials: A
authors.lastname: Lobo
authors.forename: R S
authors.initials: RS
authors.lastname: Kern
authors.forename: M F
authors.initials: MF
authors.lastname: Green
authors.forename: K H
authors.initials: KH
authors.lastname: Nuechterlein
authors.forename: T
authors.initials: T
authors.lastname: Palomo
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic / Q000592:standards; D003072:Cognition Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D004522:Educational Status; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests / Q000592:standards* / Q000706:statistics & numerical data*; D012015:Reference Standards; D012559:Schizophrenia / Q000150:complications*; D012565:Schizophrenic Psychology; D013030:Spain; D014481:United States; D055815:Young Adult